<?xml version='1.0' encoding='utf-8'?>
<document id="29272443"><sentence text="Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz."><entity charOffset="19-49" id="DDI-PubMed.29272443.s1.e0" text="Dihydroartemisinin-Piperaquine" /><entity charOffset="153-162" id="DDI-PubMed.29272443.s1.e1" text="Efavirenz" /><pair ddi="false" e1="DDI-PubMed.29272443.s1.e0" e2="DDI-PubMed.29272443.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s1.e0" e2="DDI-PubMed.29272443.s1.e1" /></sentence><sentence text="A monthly treatment course of dihydroartemisinin-piperaquine (DHA-PQ) effectively prevents malaria during pregnancy"><entity charOffset="30-48" id="DDI-PubMed.29272443.s2.e0" text="dihydroartemisinin" /><entity charOffset="49-60" id="DDI-PubMed.29272443.s2.e1" text="piperaquine" /><entity charOffset="62-68" id="DDI-PubMed.29272443.s2.e2" text="DHA-PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s2.e0" e2="DDI-PubMed.29272443.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s2.e0" e2="DDI-PubMed.29272443.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s2.e0" e2="DDI-PubMed.29272443.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29272443.s2.e1" e2="DDI-PubMed.29272443.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s2.e1" e2="DDI-PubMed.29272443.s2.e2" /></sentence><sentence text=" However, a drug-drug interaction pharmacokinetic (PK) study found that pregnant human immunodeficiency virus (HIV)-infected women receiving efavirenz-based antiretroviral therapy (ART) had markedly reduced piperaquine (PQ) exposure"><entity charOffset="141-150" id="DDI-PubMed.29272443.s3.e0" text="efavirenz" /><entity charOffset="207-218" id="DDI-PubMed.29272443.s3.e1" text="piperaquine" /><entity charOffset="220-222" id="DDI-PubMed.29272443.s3.e2" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s3.e0" e2="DDI-PubMed.29272443.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s3.e0" e2="DDI-PubMed.29272443.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s3.e0" e2="DDI-PubMed.29272443.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29272443.s3.e1" e2="DDI-PubMed.29272443.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s3.e1" e2="DDI-PubMed.29272443.s3.e2" /></sentence><sentence text=" This suggests the need for alternative DHA-PQ chemoprevention regimens in this population"><entity charOffset="44-45" id="DDI-PubMed.29272443.s4.e0" text="PQ" /></sentence><sentence text="" /><sentence text="Eighty-three HIV-infected pregnant women who received monthly DHA-PQ and efavirenz contributed longitudinal PK and corrected QT interval (QTc) (n = 25) data"><entity charOffset="73-82" id="DDI-PubMed.29272443.s6.e0" text="efavirenz" /><entity charOffset="66-74" id="DDI-PubMed.29272443.s6.e1" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s6.e1" e2="DDI-PubMed.29272443.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s6.e1" e2="DDI-PubMed.29272443.s6.e0" /></sentence><sentence text=" Population PK and PK-QTc models for PQ were developed to consider the benefits (protective PQ coverage) and risks (QTc prolongation) of alternative DHA-PQ chemoprevention regimens"><entity charOffset="37-38" id="DDI-PubMed.29272443.s7.e0" text="PQ" /><entity charOffset="92-93" id="DDI-PubMed.29272443.s7.e1" text="PQ" /><entity charOffset="153-154" id="DDI-PubMed.29272443.s7.e2" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s7.e0" e2="DDI-PubMed.29272443.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s7.e0" e2="DDI-PubMed.29272443.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s7.e0" e2="DDI-PubMed.29272443.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29272443.s7.e1" e2="DDI-PubMed.29272443.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s7.e1" e2="DDI-PubMed.29272443.s7.e2" /></sentence><sentence text=" Protective PQ coverage was defined as maintaining a concentration &gt;10 ng/mL for &gt;95% of the chemoprevention period"><entity charOffset="12-13" id="DDI-PubMed.29272443.s8.e0" text="PQ" /></sentence><sentence text="" /><sentence text="PQ clearance was 4540 L/day"><entity charOffset="0-1" id="DDI-PubMed.29272443.s10.e0" text="PQ" /></sentence><sentence text=" With monthly DHA-PQ (2880 mg PQ), &lt;1% of women achieved defined protective PQ coverage"><entity charOffset="18-19" id="DDI-PubMed.29272443.s11.e0" text="PQ" /><entity charOffset="30-31" id="DDI-PubMed.29272443.s11.e1" text="PQ" /><entity charOffset="76-77" id="DDI-PubMed.29272443.s11.e2" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s11.e0" e2="DDI-PubMed.29272443.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s11.e0" e2="DDI-PubMed.29272443.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s11.e0" e2="DDI-PubMed.29272443.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29272443.s11.e1" e2="DDI-PubMed.29272443.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s11.e1" e2="DDI-PubMed.29272443.s11.e2" /></sentence><sentence text=" Weekly (960 mg PQ) or low-dose daily (320 or 160 mg PQ) regimens achieved protective PQ coverage for 34% and &gt;96% of women, respectively"><entity charOffset="16-17" id="DDI-PubMed.29272443.s12.e0" text="PQ" /><entity charOffset="53-54" id="DDI-PubMed.29272443.s12.e1" text="PQ" /><entity charOffset="86-87" id="DDI-PubMed.29272443.s12.e2" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s12.e0" e2="DDI-PubMed.29272443.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s12.e0" e2="DDI-PubMed.29272443.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s12.e0" e2="DDI-PubMed.29272443.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29272443.s12.e1" e2="DDI-PubMed.29272443.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29272443.s12.e1" e2="DDI-PubMed.29272443.s12.e2" /></sentence><sentence text=" All regimens were safe, with ≤2% of women predicted to have ≥30 msec QTc increase" /><sentence text="" /><sentence text="For HIV-infected pregnant women receiving efavirenz, low daily DHA-PQ dosing was predicted to improve protection against parasitemia and reduce risk of toxicity compared to monthly dosing"><entity charOffset="42-51" id="DDI-PubMed.29272443.s15.e0" text="efavirenz" /><entity charOffset="67-75" id="DDI-PubMed.29272443.s15.e1" text="PQ" /><pair ddi="false" e1="DDI-PubMed.29272443.s15.e0" e2="DDI-PubMed.29272443.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29272443.s15.e0" e2="DDI-PubMed.29272443.s15.e1" /></sentence><sentence text="" /><sentence text="NCT02282293" /><sentence text="" /></document>